Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $18.3M | $18.7M | $21.4M | $32.5M | $422M | $993M | $619M | $289M | $283M | $323M |
| Revenue growth | — | 2.5% | 14.0% | 52.3% | 1196.5% | 135.4% | -37.6% | -53.3% | -2.0% | 13.8% |
| Gross profit | $11.6M | $10.2M | $10.7M | $18.4M | $332M | $777M | $367M | $104M | $107M | $131M |
| Gross margin | 63.2% | 54.3% | 49.9% | 56.6% | 78.7% | 78.3% | 59.3% | 36.1% | 37.8% | 40.6% |
| Operating income | $918K | -$3.48M | -$5.07M | -$428K | $290M | $676M | $179M | -$196M | -$73.9M | -$91.1M |
| Operating margin | 5.0% | -18.6% | -23.7% | -1.3% | 68.8% | 68.1% | 28.8% | -67.6% | -26.1% | -28.2% |
| Net income | -$5.35M | -$2.51M | -$5.61M | -$411K | $214M | $507M | $143M | -$168M | -$42.7M | -$60.5M |
| Net margin | -29.3% | -13.4% | -26.3% | -1.3% | 50.8% | 51.1% | 23.2% | -58.0% | -15.1% | -18.8% |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $4.41M | $1.33M | -$675K | $5.52M | $141M | $539M | $254M | $27.0M | $21.1M | -$102M |
| Capital expenditures | $3.79M | $2.90M | $2.32M | $1.18M | $35.1M | $23.8M | $18.8M | $22.2M | $40.3M | $22.6M |
| Free cash flow | $617K | -$1.56M | -$3.00M | $4.33M | $105M | $515M | $235M | $4.80M | -$19.3M | -$124M |
| Share buybacks | — | — | — | $21.0K | $62.0K | — | $74.3M | $25.1M | $225K | $10.9M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $7.90M | $6.49M | $6.74M | $12.0M | $87.4M | $165M | $79.5M | $97.5M | $55.1M | $50.2M |
| Total assets | $58.0M | $57.2M | $53.9M | $88.8M | $700M | $1.28B | $1.39B | $1.24B | $1.22B | $1.21B |
| Total liabilities | $3.56M | $3.01M | $2.75M | $5.98M | $131M | $113M | $116M | $102M | $90.8M | $107M |
| Shareholders' equity | $54.5M | $54.2M | $51.2M | $82.8M | $569M | $1.16B | $1.27B | $1.14B | $1.13B | $1.11B |
| Retained earnings | -$55.2M | -$57.7M | -$63.0M | -$63.4M | $151M | $658M | $801M | $633M | $590M | $530M |
| Shares (wtd avg diluted) | 17.7M | 17.7M | 18.0M | 18.7M | 24.1M | 31.0M | 31.0M | 29.8M | 30.2M | 30.8M |
Every figure is extracted from Fulgent Genetics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.